Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Summative outcomes: The proportion of patients with current LDL-c measurements and patients prescribed lipid lowering medications from baseline to the end of intervention period

From: Implementing electronic clinical reminders for lipid management in patients with ischemic heart disease in the veterans health administration: QUERI Series

  Intervention versus Comparison Individual Intervention Sites Individual Comparison Sites
  Intervention Site A Site B Site C Site D Site E Site F
Odds ratio for change from baseline to end of intervention without adjusting for degree of implementation (95% confidence intervals)*
Effect on proportion of patients with current LDL-c from baseline to end of intervention period¶ 1.96 (1.34,2.88) 1.45 (1.38,1.52) 1.57 (1.44,1.72) 1.64 (1.53,1.75) 0.57 (0.50,0.66) 0.67 (0.65,0.68) Reference
Effect on proportion of patients on lipid-lowering medications from baseline to intervention period¶ 0.92 (0.72,1.19) 0.89 (0.87,0.91) 1.10 (1.01,1.20) 0.54 (0.53,0.56) 1.30 (1.07,1.57) 0.68 (0.66,0.71) Reference
Odds ratio for change from baseline to end of intervention adjusting for provider self-reported amount of use of IHD reminder (95% CI)
Effect on proportion of patients with current LDL-c from baseline to end of intervention period 2.35 (1.96,2.81) 1.33 (0.93,1.89) 1.77 (1.11,2.82) 1.46 (0.77,2.76) 0.34 (0.27,0.43) 0.58 (0.45,0.75) Reference
Effect on proportion of patients on lipid-lowering medications from baseline to intervention period 0.87 (0.67,1.13) 0.85 (0.71,1.03) 1.05 (0.82,1.35) 0.46 (0.34,0.61) 1.35 (0.97,1.90) 0.66 (0.59,0.75) Reference
  1. *Adjusted for patient baseline and facility characteristics in Table 2; odds ratios significant at p < 0.05 bolded
  2. §Intra-class correlation for measurement change was 0.08, 95% CI 0.00 – 0.18
  3. ¶Intra-class correlation for treatment change was 0.02, 95% CI 0.00 – 0.05